Eli Lilly Faces Setback as CVS Drops Zepbound Coverage
Eli Lilly’s obesity drug Zepbound loses CVS coverage, raising concerns over sales momentum as competition with Novo Nordisk’s Wegovy intensifies. Eli Lilly Faces Fresh Hurdles as CVS Cuts Zepbound from … Read More